-+ 0.00%
-+ 0.00%
-+ 0.00%
Yuandong Biotech announced that aminophen oxycodone extended-release tablets, a class 2 improved new drug independently developed by the company, passed through medical insurance negotiations and were included in the 2026 national medical insurance catalogue for the first time. The medical insurance category is Class B, and the payment standard is 8.00 yuan/tablet. The agreement is valid from January 1, 2027 to December 31, 2028. This drug is a Class II psychotropic drug. It was approved for marketing in April 2026. The company is the first domestic company to be approved for this drug. The inclusion of medical insurance this time will help expand the commercialization of the drug. It will not have a significant impact on the company's business performance in 2026, and there is uncertainty about future sales.
Share
Listen to the news
Yuandong Biotech announced that aminophen oxycodone extended-release tablets, a class 2 improved new drug independently developed by the company, passed through medical insurance negotiations and were first included in the 2026 edition of the national medical insurance catalogue. The medical insurance category is Class B, and the payment standard is 8.00 yuan/tablet. The agreement is valid from January 1, 2027 to December 31, 2028. This drug is a Class II psychotropic drug. It was approved for marketing in April 2026. The company is the first domestic company to be approved for this drug. The inclusion of medical insurance this time will help expand the commercialization of the drug. It will not have a significant impact on the company's business performance in 2026, and there is uncertainty about future sales.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending